Grundy S M, Mazzaferri E L
University of Texas Southwestern Medical Center at Dallas, USA.
Hosp Pract (1995). 1996 Jun 15;31(6):43-8, 53-5, 59; discussion 60.
The past decade has seen a major shift in management: Trials of HMG-CoA reductase inhibitors have suggested that cholesterol reduction offers greater protection against coronary artery disease than does antihypertensive therapy. Five patient vignettes provide guidelines for initiating therapy. The agents should be prescribed with restraint, often not until other measures have been exhausted.
